[go: up one dir, main page]

LT2691155T - Maitanzinoido antikūno konjugatų gavimas vienpakopiu būdu - Google Patents

Maitanzinoido antikūno konjugatų gavimas vienpakopiu būdu

Info

Publication number
LT2691155T
LT2691155T LTEP12714160.4T LT12714160T LT2691155T LT 2691155 T LT2691155 T LT 2691155T LT 12714160 T LT12714160 T LT 12714160T LT 2691155 T LT2691155 T LT 2691155T
Authority
LT
Lithuania
Prior art keywords
preparation
step process
antibody conjugates
maytansinoid antibody
maytansinoid
Prior art date
Application number
LTEP12714160.4T
Other languages
English (en)
Inventor
Xinfang LI
Jared M. WORFUL
Original Assignee
Immunogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen, Inc. filed Critical Immunogen, Inc.
Priority claimed from PCT/US2012/031243 external-priority patent/WO2012135517A2/en
Publication of LT2691155T publication Critical patent/LT2691155T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
LTEP12714160.4T 2011-03-29 2012-03-29 Maitanzinoido antikūno konjugatų gavimas vienpakopiu būdu LT2691155T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161468997P 2011-03-29 2011-03-29
PCT/US2012/031243 WO2012135517A2 (en) 2011-03-29 2012-03-29 Preparation of maytansinoid antibody conjugates by a one-step process

Publications (1)

Publication Number Publication Date
LT2691155T true LT2691155T (lt) 2019-02-25

Family

ID=46928080

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP12714160.4T LT2691155T (lt) 2011-03-29 2012-03-29 Maitanzinoido antikūno konjugatų gavimas vienpakopiu būdu

Country Status (26)

Country Link
US (7) US8795673B2 (lt)
EP (2) EP3545977A1 (lt)
JP (5) JP6000329B2 (lt)
KR (6) KR102272828B1 (lt)
CN (2) CN103717262B (lt)
AU (5) AU2012236398B2 (lt)
CA (1) CA2831467C (lt)
CY (1) CY1121321T1 (lt)
DK (1) DK2691155T3 (lt)
EA (2) EA201991268A3 (lt)
ES (1) ES2709577T3 (lt)
HR (1) HRP20190243T1 (lt)
HU (1) HUE041384T2 (lt)
IL (3) IL228559A (lt)
LT (1) LT2691155T (lt)
ME (1) ME03353B (lt)
MX (2) MX369659B (lt)
NZ (1) NZ726386A (lt)
PL (1) PL2691155T3 (lt)
PT (1) PT2691155T (lt)
RS (1) RS58367B1 (lt)
SI (1) SI2691155T1 (lt)
SM (1) SMT201900114T1 (lt)
TR (1) TR201902180T4 (lt)
UA (1) UA116524C2 (lt)
ZA (1) ZA201605918B (lt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5149620B2 (ja) 2004-07-23 2013-02-20 エンドサイト，インコーポレイテッド ２価リンカーおよびその結合体
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
NZ716641A (en) 2005-08-24 2017-06-30 Immunogen Inc Process for preparing maytansinoid antibody conjugates
NZ599239A (en) 2007-03-14 2013-10-25 Endocyte Inc Binding ligand linked drug delivery conjugates of tubulysins
JP5690589B2 (ja) 2007-06-25 2015-03-25 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 親水性スペーサーリンカーを含有する結合体
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
DK2437790T3 (da) 2009-06-03 2019-05-20 Immunogen Inc Konjugeringsfremgangsmåder
NZ724971A (en) 2010-02-24 2019-06-28 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof
KR101764572B1 (ko) 2010-03-12 2017-08-03 이뮤노젠 아이엔씨 Ｃｄ３７―결합 분자 및 이의 면역접합체
RS58367B1 (sr) 2011-03-29 2019-03-29 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
PL2694106T3 (pl) * 2011-04-01 2018-06-29 Immunogen, Inc. Sposoby zwiększania skuteczności terapii przeciwnowotworowej opartej na receptorze folr1
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
CA2883222C (en) 2012-08-31 2021-12-14 Immunogen, Inc. Diagnostic assays and kits for detection of folate receptor 1
CA2886993A1 (en) 2012-10-04 2014-04-10 Immunogen, Inc. Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
US20150306242A1 (en) * 2012-10-04 2015-10-29 Immunogen, Inc. Process for preparing stable antibody maytansinoid conjugates
RU2015116883A (ru) * 2012-10-04 2016-11-27 Иммуноджен, Инк. Применение ионообменной мембраны для удаления примесей из конъюгатов клеточносвязывающего агента с цитотоксическим агентом
JP2015536323A (ja) 2012-10-16 2015-12-21 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 非天然アミノ酸を含む薬物送達結合体および使用方法
US8769557B1 (en) 2012-12-27 2014-07-01 The Nielsen Company (Us), Llc Methods and apparatus to determine engagement levels of audience members
JP6423804B2 (ja) 2013-02-28 2018-11-14 イミュノジェン・インコーポレーテッド 細胞結合剤及び細胞毒性剤を含む複合体
EP3566750A3 (en) 2013-02-28 2020-04-08 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
MA38396B1 (fr) 2013-03-15 2019-05-31 Novartis Ag Anticorps medicamenteux conjugues et leurs compositions pharmaceutiques pour traiter un cancer positif a ckit
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
KR102585409B1 (ko) 2013-08-30 2023-10-05 이뮤노젠 아이엔씨 엽산 수용체 1의 검출을 위한 항체 및 분석
TWI541022B (zh) 2013-12-18 2016-07-11 應克隆公司 針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法
MY178160A (en) 2014-03-11 2020-10-06 Regeneron Pharma Anti-egfrviii antibodies and uses thereof
EP3682904A1 (en) 2014-06-30 2020-07-22 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
KR20170040249A (ko) 2014-08-12 2017-04-12 노파르티스 아게 항-cdh6 항체 약물 접합체
WO2016065456A1 (en) * 2014-10-31 2016-05-06 Formation Biologics Inc. Egfr antibody-based combination therapy
CN106267225B (zh) * 2015-05-29 2020-03-06 上海新理念生物医药科技有限公司 三马来酰亚胺型连接子及其应用
TW201711702A (zh) 2015-06-04 2017-04-01 應克隆公司 使用針對纖維母細胞生長因子受體３（ｆｇｆｒ３）之化合物的療法
AU2016276158B2 (en) 2015-06-08 2022-06-30 Debiopharm International, S.A. Anti-CD37 immunoconjugate and anti-CD20 antibody combinations
WO2016203432A1 (en) 2015-06-17 2016-12-22 Novartis Ag Antibody drug conjugates
CA2995243A1 (en) 2015-08-28 2017-03-09 Debiopharm International, S.A. Antibodies and assays for detection of cd37
WO2017049149A1 (en) 2015-09-17 2017-03-23 Immunogen, Inc. Therapeutic combinations comprising anti-folr1 immunoconjugates
PT3380525T (pt) 2015-11-25 2024-02-05 Immunogen Inc Formulações farmacêuticas e métodos que as utilizam
KR20180105233A (ko) * 2016-02-05 2018-09-27 이뮤노젠 아이엔씨 세포 결합제-세포독성제 접합체를 제조하기 위한 효율적인 방법
CN108421048B (zh) * 2016-09-28 2021-04-20 首都医科大学附属北京世纪坛医院 纳米活性碳靶向药物递送系统、制备方法及其用途
JP2020510608A (ja) 2016-11-02 2020-04-09 デビオファーム インターナショナル， エス． アー． 抗ｃｄ３７イムノコンジュゲート療法を改善するための方法
US10864279B2 (en) 2016-12-16 2020-12-15 Industrial Technology Research Institute Linker-drug and antibody-drug conjugate (ADC) employing the same
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
CN116785450A (zh) * 2017-02-28 2023-09-22 伊缪诺金公司 具有自分解肽接头的类美登素衍生物和其缀合物
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
EP3740233A4 (en) * 2018-01-18 2021-11-24 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD134 + CELLS
EP3552631A1 (en) 2018-04-10 2019-10-16 Inatherys Antibody-drug conjugates and their uses for the treatment of cancer
AU2019277836A1 (en) 2018-05-30 2021-01-21 Debiopharm International, S.A. Anti-CD37 immunoconjugate dosing regimens
CN111620927B (zh) * 2019-05-20 2022-11-11 烟台迈百瑞国际生物医药股份有限公司 一种抗体药物偶联物中间体的一锅法制备工艺
US20220257766A1 (en) * 2019-06-25 2022-08-18 Tva (Abc), Llc Sstr-targeted conjugates and formulations thereof
PE20220563A1 (es) 2019-07-10 2022-04-13 Cybrexa 2 Inc Conjugados peptidicos de citotoxinas como terapeuticos
CA3146385A1 (en) 2019-07-10 2021-01-14 Cybrexa 3, Inc. Peptide conjugates of microtubule-targeting agents as therapeutics
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
KR20230125129A (ko) 2022-02-17 2023-08-29 주식회사 노벨티노빌리티 항체-약물 접합체
WO2025019790A1 (en) 2023-07-19 2025-01-23 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc

Family Cites Families (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1043543A (en) 1912-02-15 1912-11-05 Robert H Shaw Poultry-house door.
SE430062B (sv) 1977-03-04 1983-10-17 Pharmacia Fine Chemicals Ab Kopplings- eller tioleringsreagens
US4137230A (en) * 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4563304A (en) 1981-02-27 1986-01-07 Pharmacia Fine Chemicals Ab Pyridine compounds modifying proteins, polypeptides or polysaccharides
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4664911A (en) 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
DE3587294T2 (de) 1985-01-22 1993-09-30 Saint Gobain Vitrage Verfahren zur Herstellung einer dünnen Metalloxidbeschichtung auf einem Substrat, insbesondere Glas und deren Verwendung als Verglasung.
GB8600582D0 (en) 1986-01-10 1986-02-19 Ca Minister Nat Defence Purifying biological materials
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4859449A (en) 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
US5241078A (en) 1988-06-14 1993-08-31 Cetus Oncology Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5024834A (en) 1988-07-12 1991-06-18 Cetus Corporation Thioether linked immunotoxin conjugates
CA2006408A1 (en) 1988-12-27 1990-06-27 Susumu Iwasa Bispecific monoclonal antibody, its production and use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5714149A (en) 1989-02-10 1998-02-03 Celltech Therapeutics Limited Crosslinked antibodies and processes for their preparation
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6316003B1 (en) 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5137877B1 (en) 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
CA2048078A1 (en) 1990-11-15 1992-05-16 Wolfgang A. Wrasidlo Chemical modification of antibodies for creation of immunoconjugates
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
SE9102074D0 (sv) 1991-07-03 1991-07-03 Kabi Pharmacia Ab Tomour antigen specific antibody
SE470006B (sv) * 1991-09-26 1993-10-25 Corline Systems Ab Nytt konjugat, dess framställning och användning samt substrat preparerat med konjugatet
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5556623A (en) * 1993-03-30 1996-09-17 Eli Lilly And Company Antibody-drug conjugates
IL111748A0 (en) 1993-12-03 1995-01-24 Zeneca Ltd Proteins
US5580853A (en) 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
US5747446A (en) 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
US5919758A (en) 1994-03-22 1999-07-06 Beth Israel Deaconess Medical Center Modified polypeptides with altered biological activity
US5612474A (en) 1994-06-30 1997-03-18 Eli Lilly And Company Acid labile immunoconjugate intermediates
AU5908296A (en) * 1995-05-31 1996-12-24 Fred Hutchinson Cancer Research Center Compositions and methods for targeted delivery of effector m olecules
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5958872A (en) 1996-04-01 1999-09-28 Apoptosis Technology, Inc. Active survival domains of IGF-IR and methods of use
WO1998026747A2 (en) 1996-12-17 1998-06-25 Terman David S Superantigen based methods and compositions for treatment of diseases
US6462070B1 (en) * 1997-03-06 2002-10-08 The General Hospital Corporation Photosensitizer conjugates for pathogen targeting
US6371975B2 (en) * 1998-11-06 2002-04-16 Neomend, Inc. Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers
ES2231991T3 (es) * 1997-06-11 2005-05-16 Borean Pharma A/S Modulo de trimerizacion.
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US5958677A (en) 1997-07-28 1999-09-28 The New York Blood Center, Inc. Method for purifying viral nucleic acids
EP1005569A2 (en) 1997-08-01 2000-06-07 MorphoSys AG Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
US5965714A (en) 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
KR100680014B1 (ko) * 1997-10-03 2007-02-09 갈레니카 파마슈티칼스 인크. 이민 형성 폴리사카라이드, 이의 제조 방법 및 이것의 아쥬반트 및 면역자극제로서의 용도
US6121236A (en) * 1998-03-24 2000-09-19 The Children's Medical Center Corporation Multivalent ligands which modulate angiogenesis
CA2329897A1 (en) * 1998-04-28 1999-11-04 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
US5981564A (en) * 1998-07-01 1999-11-09 Universite Laval Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
US7067109B1 (en) 1998-07-13 2006-06-27 Board Of Regents, The University Of Texas System Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids
TW593241B (en) 1999-04-20 2004-06-21 Hoffmann La Roche Carbamic acid derivatives
AUPQ014799A0 (en) * 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
EP1229934B1 (en) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
DE60032633T2 (de) 1999-11-24 2007-10-04 Immunogen Inc., Cambridge Zytotoxische mittel, die taxane enthalten und ihre therapeutische anwendung
ES2274823T3 (es) 1999-12-29 2007-06-01 Immunogen, Inc. Agentes cototoxicos que comprenden doxorrubicinas y daunorrubicinas y su utilizacion terapeutica.
AU2001236892A1 (en) 2000-02-08 2001-08-20 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US6596503B1 (en) 2000-08-18 2003-07-22 East Carolina University Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof
US20060062786A1 (en) 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
GEP20084484B (en) 2001-01-05 2008-09-25 Pfizer Antibodies to insulin-like growth factor i receptor
NZ545176A (en) 2001-01-29 2008-05-30 Biogen Idec Inc Modified antibodies reactive with CD20 and methods of use
CA2436408A1 (en) * 2001-02-07 2002-12-12 Beth Israel Deaconess Medical Center Modified psma ligands and uses related thereto
US20020197261A1 (en) 2001-04-26 2002-12-26 Chun Li Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
EP1392361A4 (en) 2001-05-11 2009-08-05 Univ Texas ANTI-CD26 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH CD26 EXPRESSIVE CELLS
EP1258255A1 (en) 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
JP4619651B2 (ja) 2001-06-01 2011-01-26 コーネル・リサーチ・ファンデーション・インコーポレイテッド 前立腺特異的膜抗原に対する修飾抗体およびその使用
US6576802B2 (en) 2001-06-04 2003-06-10 Shell Oil Company One-step production of 1, 3-propanediol from ethylene oxide and syngas with a catalyst with a phospholanoalkane ligand
US7157443B2 (en) 2001-12-11 2007-01-02 Merck & Co., Inc. Staphylococcus aureus exopolysaccharide and process
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
EP1467758A4 (en) 2002-01-03 2007-11-14 Smithkline Beecham Corp PREPARATION OF IMMUNOCONJUGATES
US7591994B2 (en) * 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
US6534660B1 (en) 2002-04-05 2003-03-18 Immunogen, Inc. CC-1065 analog synthesis
HUE025101T2 (en) 2002-04-26 2016-02-29 Genentech Inc Purification of proteins other than affinity purification
ES2593304T3 (es) 2002-05-02 2016-12-07 Wyeth Holdings Llc Conjugados de transportador derivado de caliqueamicina
US20090068178A1 (en) 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
US6596757B1 (en) 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
JP2005530845A (ja) 2002-06-21 2005-10-13 アイデック ファーマシューティカルズ コーポレイション 抗体を濃縮するための緩衝化処方物およびその使用方法
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
AU2003259163B2 (en) 2002-08-16 2008-07-03 Immunogen, Inc. Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
ES2314238T3 (es) * 2002-10-08 2009-03-16 Fresenius Kabi Deutschland Gmbh Conjugados de oligosacaridos farmaceuticamente activos.
ES2640279T3 (es) * 2002-10-30 2017-11-02 Nuevolution A/S Procedimiento para la síntesis de un complejo bifuncional
CN1795009B (zh) 2002-11-07 2014-07-09 伊谬诺金公司 抗-cd33抗体及其用途
CN102940889A (zh) 2003-05-14 2013-02-27 伊缪诺金公司 药物缀合物组合物
US8088387B2 (en) * 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
AU2004240541B2 (en) 2003-05-20 2009-08-20 Immunogen, Inc. Improved cytotoxic agents comprising new maytansinoids
CN102675462A (zh) 2003-06-27 2012-09-19 艾默根佛蒙特有限公司 针对表皮生长因子受体的缺失突变体的抗体及其使用
US20050074425A1 (en) * 2003-07-02 2005-04-07 Polycord, Inc. Method for delivering polymerized therapeutic agent compositions and compositions thereof
CN1878568A (zh) * 2003-11-05 2006-12-13 盘林京有限公司 Cdim结合抗体的增强的b细胞细胞毒性
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
US20110064754A1 (en) 2005-03-03 2011-03-17 Center For Molecular Medicine And Immunology Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
WO2005094882A1 (en) 2004-03-03 2005-10-13 Millennium Pharmaceuticals, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
JP2008505853A (ja) 2004-04-13 2008-02-28 クインテセンス バイオサイエンシーズ インコーポレーティッド 細胞傷害性薬剤としての非天然のリボヌクレアーゼ複合体
US20060073528A1 (en) * 2004-05-14 2006-04-06 Jean-Michel Lecerf Measurement methods
RU2402548C2 (ru) 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
US7517903B2 (en) 2004-05-19 2009-04-14 Medarex, Inc. Cytotoxic compounds and conjugates
EP2286844A3 (en) 2004-06-01 2012-08-22 Genentech, Inc. Antibody-drug conjugates and methods
CA2486285C (en) 2004-08-30 2017-03-07 Viktor S. Goldmakher Immunoconjugates targeting syndecan-1 expressing cells and use thereof
AR052774A1 (es) 2004-10-08 2007-04-04 Wyeth Corp Inmunoterapia para trastornos autoinmunes
JP2008521828A (ja) 2004-11-29 2008-06-26 シアトル ジェネティックス， インコーポレイテッド 操作された抗体およびイムノコンジュゲート
US8603483B2 (en) 2004-12-09 2013-12-10 Janssen Biotech, Inc. Anti-integrin immunoconjugates, methods and uses
US7408030B2 (en) 2005-01-13 2008-08-05 North Carolina State University Purification of immunoglobulins using affinity chromatography and peptide ligands
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
EP2468304A3 (en) 2005-02-11 2012-09-26 ImmunoGen, Inc. Process for preparing stable drug conjugates
CA2600929A1 (en) 2005-03-04 2006-09-14 Biogen Idec Ma Inc. Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
EA200702239A1 (ru) 2005-04-15 2008-10-30 Иммьюноджен, Инк. Уничтожение гетерогенной или смешанной клеточной популяции в опухолях
GB2427360A (en) * 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
SI2233156T1 (sl) 2005-07-15 2013-09-30 Angiochem Inc. Uporaba polipeptidov aprotinina kot nosilce v farmacevtskih konjugatih
JP2009503105A (ja) * 2005-08-03 2009-01-29 イミュノジェン・インコーポレーテッド 免疫複合体製剤
WO2007019273A2 (en) * 2005-08-04 2007-02-15 Albert Einstein College Of Medicine Of Yeshiva University Phosphorylation of tau by abl
NZ716641A (en) 2005-08-24 2017-06-30 Immunogen Inc Process for preparing maytansinoid antibody conjugates
CN101443044A (zh) * 2005-09-22 2009-05-27 哈达斯特医学研究服务与开发有限公司 治疗活性化合物的葡聚糖和阿拉伯半乳聚糖结合物
ES2416136T3 (es) 2005-09-26 2013-07-30 Medarex, Inc. Conjugados de anticuerpo-fármaco y su uso
WO2007059195A1 (en) 2005-11-14 2007-05-24 University Of Southern California Integrin-binding small molecules
US7964415B2 (en) * 2006-04-26 2011-06-21 Cardiogenics Inc. Stable water-soluble polyethylenimine conjugates and methods of use thereof
JP2009538629A (ja) 2006-05-30 2009-11-12 ジェネンテック・インコーポレーテッド 抗体およびイムノコンジュゲートとこれらの使用方法
MX2009000709A (es) 2006-07-18 2009-02-04 Sanofi Aventis Anticuerpo antagonista contra epha2 para el tratamiento de cancer.
US20080213349A1 (en) * 2006-09-11 2008-09-04 Deepak Ramesh Thakker Liposome Complexes Containing Pharmaceutical Agents and Methods
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
PL2019104T3 (pl) 2007-07-19 2014-03-31 Sanofi Sa Środki cytotoksyczne obejmujące nowe pochodne tomaymycyny i ich zastosowanie terapeutyczne
SG189817A1 (en) 2008-04-30 2013-05-31 Immunogen Inc Potent conjugates and hydrophilic linkers
KR101764081B1 (ko) * 2008-04-30 2017-08-01 이뮤노젠 아이엔씨 가교제 및 그 용도
GB0811743D0 (en) * 2008-06-26 2008-07-30 Hemosol Biopharma Inc Composition
CN102215820A (zh) * 2008-11-17 2011-10-12 安龙制药公司 用于核酸输送系统的可释放融合脂质
ES2604668T3 (es) 2009-02-05 2017-03-08 Immunogen, Inc. Nuevos derivados de benzodiacepina
UY32560A (es) 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
DK2437790T3 (da) 2009-06-03 2019-05-20 Immunogen Inc Konjugeringsfremgangsmåder
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
TW201117814A (en) 2009-10-02 2011-06-01 Sanofi Aventis New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody
TW201116297A (en) 2009-10-02 2011-05-16 Sanofi Aventis Antibodies that specifically bind to the EphA2 receptor
NZ724971A (en) 2010-02-24 2019-06-28 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof
KR101764572B1 (ko) 2010-03-12 2017-08-03 이뮤노젠 아이엔씨 Ｃｄ３７―결합 분자 및 이의 면역접합체
KR20110103182A (ko) 2010-03-12 2011-09-20 삼성전자주식회사 입체 영상 표시 장치
WO2012019024A2 (en) 2010-08-04 2012-02-09 Immunogen, Inc. Her3-binding molecules and immunoconjugates thereof
US20120149732A1 (en) * 2010-12-14 2012-06-14 Alexander Chucholowski Multifunctional linkers and methods for the use thereof
KR20190089048A (ko) * 2011-02-15 2019-07-29 이뮤노젠 아이엔씨 컨쥬게이트의 제조방법
SG193997A1 (en) 2011-03-29 2013-11-29 Immunogen Inc Process for manufacturing conjugates of improved homogeneity
EA025786B1 (ru) 2011-03-29 2017-01-30 Иммуноджен, Инк. Способ производства конъюгатов с улучшенной гомогенностью
RS58367B1 (sr) 2011-03-29 2019-03-29 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
PL2694106T3 (pl) 2011-04-01 2018-06-29 Immunogen, Inc. Sposoby zwiększania skuteczności terapii przeciwnowotworowej opartej na receptorze folr1
US20130071482A1 (en) * 2011-09-20 2013-03-21 The University Of Kentucky Research Foundation Block copolymer cross-linked nanoassemblies as modular delivery vehicles
BR112014014464A2 (pt) 2011-12-13 2017-06-13 Immunogen Inc uso de n-hidroxisuccinimida para melhorar a estabilidade do conjugado
US20150306242A1 (en) 2012-10-04 2015-10-29 Immunogen, Inc. Process for preparing stable antibody maytansinoid conjugates
RU2015116883A (ru) 2012-10-04 2016-11-27 Иммуноджен, Инк. Применение ионообменной мембраны для удаления примесей из конъюгатов клеточносвязывающего агента с цитотоксическим агентом
CA2886993A1 (en) 2012-10-04 2014-04-10 Immunogen, Inc. Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
WO2014086835A1 (en) * 2012-12-05 2014-06-12 Ruprecht-Karls-Universität Heidelberg Conjugates of proteins and multivalent cell-penetrating peptides and their uses

Also Published As

Publication number Publication date
EP3545977A1 (en) 2019-10-02
CN103717262B (zh) 2017-09-15
EA201991268A3 (ru) 2020-01-31
BR112013025225A2 (pt) 2018-09-25
JP2019056003A (ja) 2019-04-11
TR201902180T4 (tr) 2019-03-21
US20240156976A1 (en) 2024-05-16
JP2016204385A (ja) 2016-12-08
US11744900B2 (en) 2023-09-05
KR20200042965A (ko) 2020-04-24
NZ712414A (en) 2016-12-23
AU2012236398A1 (en) 2013-05-16
IL250723B (en) 2018-05-31
EA201391398A1 (ru) 2014-02-28
IL258929A (en) 2018-07-31
MX369659B (es) 2019-11-15
IL258929B (en) 2019-03-31
KR102351886B1 (ko) 2022-01-17
JP6456885B2 (ja) 2019-01-23
AU2016202832A1 (en) 2016-05-19
US11090390B2 (en) 2021-08-17
JP2023083504A (ja) 2023-06-15
ES2709577T3 (es) 2019-04-16
US20140309406A1 (en) 2014-10-16
JP2021035990A (ja) 2021-03-04
HUE041384T2 (hu) 2019-05-28
AU2018211331A1 (en) 2018-08-23
US20220133899A1 (en) 2022-05-05
EA033468B1 (ru) 2019-10-31
KR102103302B1 (ko) 2020-04-23
UA116524C2 (uk) 2018-04-10
JP6797885B2 (ja) 2020-12-09
HRP20190243T1 (hr) 2019-03-22
KR20220009505A (ko) 2022-01-24
CA2831467C (en) 2020-03-24
DK2691155T3 (en) 2019-03-04
AU2012236398B2 (en) 2016-02-11
CN103717262A (zh) 2014-04-09
IL228559A0 (en) 2013-12-31
JP6000329B2 (ja) 2016-09-28
EP2691155B1 (en) 2018-11-14
MX339927B (es) 2016-06-16
JP7269210B2 (ja) 2023-05-08
US20120253021A1 (en) 2012-10-04
US10435432B2 (en) 2019-10-08
CN107537040A (zh) 2018-01-05
KR20140019414A (ko) 2014-02-14
PL2691155T3 (pl) 2019-06-28
AU2020217301A1 (en) 2020-08-27
US20170037080A1 (en) 2017-02-09
US9428543B2 (en) 2016-08-30
US9914748B2 (en) 2018-03-13
CY1121321T1 (el) 2020-05-29
AU2016202832B2 (en) 2018-05-10
ME03353B (me) 2019-10-20
JP2014514294A (ja) 2014-06-19
MX2013011215A (es) 2013-10-30
IL228559A (en) 2017-03-30
AU2018211331B2 (en) 2020-05-14
IL250723A0 (en) 2017-06-29
ZA201605918B (en) 2021-07-28
US20180273581A1 (en) 2018-09-27
NZ616509A (en) 2015-10-30
KR20230128583A (ko) 2023-09-05
US20200330604A1 (en) 2020-10-22
EA201991268A2 (ru) 2019-10-31
US8795673B2 (en) 2014-08-05
NZ726386A (en) 2022-09-30
PT2691155T (pt) 2019-02-19
AU2020217301B2 (en) 2023-10-19
KR20220123130A (ko) 2022-09-05
CA2831467A1 (en) 2012-10-04
SMT201900114T1 (it) 2019-02-28
RS58367B1 (sr) 2019-03-29
KR20210082267A (ko) 2021-07-02
SI2691155T1 (sl) 2019-03-29
KR102272828B1 (ko) 2021-07-05
EP2691155A2 (en) 2014-02-05
AU2024200123A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
HRP20190243T1 (hr) Priprema konjugata antitijela majtanzinoida postupkom s jednim korakom
HRP20190576T1 (hr) Postupci pripreme konjugata
HK1221153A1 (zh) 抗體-藥物綴合物
IL230719A0 (en) highly galactosylated antibodies
IL228565A0 (en) A process for preparing conjugates with improved homogeneity
PL2912948T3 (pl) Porcjowana kapsułka do wytwarzania napoju
EP2916835A4 (en) COMPOUNDS AND METHOD FOR PRODUCING A CONJUGATE
ZA201302986B (en) Portion capsule for producing a beverage using a portion capsule
ZA201307247B (en) A novel process for preparation of polysaccharides
PL3067193T3 (pl) Produkcja kafelkowa dla pary pudełek
AP2014007692A0 (en) A process for producing tea product
EP2663568A4 (en) PROCESS FOR THE PREPARATION OF ACETALS
WO2012174549A9 (en) Blockade of eosinophil production by toll-like receptors
EP2646431A4 (en) PROCESS FOR THE PREPARATION OF PAZOPANIB USING A NEW INTERMEDIATE
EP2714696A4 (en) PROCESS FOR PREPARING ANYHYDRUGAL ALCOHOLS
PL2681199T3 (pl) Sposób wytwarzania (-)-hupercyny A
EP2663542A4 (en) PROCESS FOR PREPARING ALDITOL ACETALS
EP2776388A4 (en) AN INEDIC PROCESS FOR THE PREPARATION OF (R) -N-BENZYL-2-ACETAMIDO-3-METHOXYPROPIONAMIDE
EP2663569A4 (en) PROCESS FOR THE PREPARATION OF ALDITOL ACETALES
EP2852592A4 (en) PROCESS FOR THE PREPARATION OF VALACYCLOVIR CHLORHYDRATE
EP2702039A4 (en) PROCESS FOR THE PREPARATION OF DICYANOCARBOXYLATE DERIVATIVES
HK1201063A1 (en) Process for the preparation of a thioprecursor for statins
GB201100283D0 (en) Novel polymer conjugates and a process for their preparation
ZA201401732B (en) A process for preparation of a tea product
GB201210838D0 (en) Novel process for preparation of antibody conjugates and novel antibody conjugates